GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company focused on carbohydrate drug development, today announced that it has received a favorable decision in final and binding arbitration proceedings. The arbitration was brought by the Company against David Platt, its former CEO, who is now CEO of Pro-Pharmaceuticals, Inc. (AMEX:PRW).
